The content on this site is intended for healthcare professionals only
Dr Carlos Fernandez De Larrea presents data from the multicentre CARTBCMA-HCB-01 study during a press conference at the EHA 2022 meeting.
The study evaluated the efficacy and safety of a novel autologous CAR T-cell product (ARI0002h) targeting B-cell maturation antigen (BCMA) in patients with relapsed/refractory multiple myeloma.
Watch Dr Fernández De Larrea's interview here
Read the news story here
Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma
Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM
Understanding the remaining unmet needs in a post ASCT NDMM setting
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Multiple myeloma In Rwanda: The need for further research
